Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of guselkumab in moderate to severe hidradenitis suppurativa
NL-OMON46316Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in hidradenitis suppurativa (HS), sponsored by Janssen Pharmaceutical. Primary endpoint: Hidradenitis Suppurativa Clinical Response at Week 16. Started Nov 2018; status: completed.
02
Drugs
guselkumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON46316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46316.